Announcements Trials
Browse Landscape

Status

No longer available 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 27Expanded_access 3Observational 1

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × elotuzumab × Clear all
NCT02856438 2023-12-19

Early Patient Access Treatment Use Protocol CA204-220

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT02368301 2023-11-30

Expanded Access Treatment Protocol CA204-143

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT03126617 2021-11-29

Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡